

Name:

Asma Bandhani

Designation:

gastroenterology fellow

Institute:

Liaquat national hospital

City:

Karachi

Phone:

03332182551

Email Address:

drasmabandhani@hotmail.co.uk

Topic:

Response and complications of Different regime (sofosbuvir,velpatasvir and with or without ribavirin) in patients treated for hepatitis C on outpatient basis

All Authors:

Asma Bandani , Baseer Sultan Ahmad, Pervez Ashraf

Abstract:

Objective: The aim of this study was to assess the efficacy of sofosbuvir ,velpatasvir and with or without ribavirin for 12 weeks in individuals with chronic HCV infection.. Methods It prospective study from June 2017 to jun 2018. Adult chronic HCV infected patients including treatment naïve, relapsers and non responders with interferons were included in this study. We included only chronic HCV infection and compensated cirrhotic and decompensated cirrhotic patients All patients were evaluated before treatment with baseline CBC, PT, creatinine, LFT, albumin, TSH, RBS, HCV RNA Quantitative, HCV genotype and U/S upper abdomen. . All the patients received daily with SOF 400 mg OD, with weight based ribavirin daily for 12 weeks. Patients were closely follow up for treatment response with HCV RNA PCR for RVR, ETR and SVR response and complications. Results A Total of 134 patients were included in the study, 68(50.7%) were male, with mean age of 47 ± 1.43 years. Treatment naïve included 85(63.4%) patients where as 49 (36.6%) Included nonresponder and relapse to interferon therapy. The most prevalent genotype was 3 and 1 which included 121(93.8%) and 3(2.3%) patients respectively.RVR and ETR was achieved in 121(93.8%) and 95% patients respectively. Out of 134 patients 75 patents followed up in opd and SVR 12 was achieved, rests of patients were lost to follow-up. A total of 50 patients achieved SVR 24, rest of patients were lost to followup. A total 4 (6.5%) required dose reduction of ribavirin Conclusions All oral DAAs effectively cured HCV in patients with excellent viral clearance. Keywords:hepatitis C, oral antiviral, response, complication, direct acting.